BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38427665)

  • 21. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
    Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
    Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
    Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
    Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy.
    Sergott RC; Amorelli GM; Baranello G; Barreau E; Beres S; Kane S; Mercuri E; Orazi L; SantaMaria M; Tremolada G; Santarsiero D; Waskowska A; Yashiro S; Denk N; Fürst-Recktenwald S; Gerber M; Gorni K; Jaber B; Jacobsen B; Mueller L; Nave S; Scalco RS; Marzoli SB;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):54-65. PubMed ID: 33231373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
    Battini V; Carnovale C; Clementi E; Sessa M
    Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
    Zhao D; Long X; Zhou J; Wang J
    Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
    Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
    Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020.
    Alsuhibani A; Alrasheed M; Gari M; Hincapie AL; Guo JJ
    Int J Clin Pharm; 2022 Feb; 44(1):172-179. PubMed ID: 34564826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
    Sato K; Mano T; Iwata A; Toda T
    Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database.
    Tang L; Ding C; Li H; Yin G; Zhang H; Liu WS; Ji Y; Li H
    Expert Opin Drug Saf; 2024 Feb; 23(2):213-220. PubMed ID: 37581403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system.
    Cao B; Gu S; Shen Z; Zhang Y; Shen Y; Chen H
    Expert Opin Drug Saf; 2024 Mar; 23(3):297-303. PubMed ID: 37608560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can social media data lead to earlier detection of drug-related adverse events?
    Duh MS; Cremieux P; Audenrode MV; Vekeman F; Karner P; Zhang H; Greenberg P
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1425-1433. PubMed ID: 27601271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System.
    Min J; Osborne V; Kowalski A; Prosperi M
    Drug Saf; 2018 Mar; 41(3):313-320. PubMed ID: 29098610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.